Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

The Muscle Monitor: Early Skeletal Muscle Indicators of Insulin Resistance and Cardiometabolic Risk (MUSCLE MONITOR)

24 июня 2026 г. обновлено: University Ghent

The Muscle Phenotype and Cardiometabolic Health Monitoring Project

Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come.

Skeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status).

In the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit ~250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditions with wearable sensors.

The study has a longitudinal aspect as participants will be re-invited at 5-year intervals for up to 20 years to delineate the trajectory of metabolic health in relation to muscle phenotype measures.

The results of the project are expected to lead to significant advancements in our understanding of the importance of muscle phenotype for early-stage insulin resistance and metabolic health trajectories. Such understanding has potentially important clinical implications, as it can open new avenues for targeted interventions and individualized early preventive strategies to counter or delay the progression of insulin resistance and associated metabolic and cardiovascular disorders.

Обзор исследования

Статус

Рекрутинг

Условия

Подробное описание

The project is composed of 1) a screening visit to determine study eligibility, 2) a main test day in the lab, 3) 10 days of physical activity tracking and continuous glucose monitoring in free-living conditions and 4) a scan visit including a whole-body MRI scan and lower leg pQCT scan.

For the main lab visit the participants will arrive in the morning after an overnight fast. This visit includes measurements of anthropometrics, resting metabolic rate, resting heart rate + heart rate variability, arterial stiffness, intima media thickness, as well as blood pressure obtained in the supine position. In addition, a fasting blood sample will be obtained followed by a 2-h glucose tolerance test with concomitant questionnaires provided in writing on basic demographics, physical activity level, sleep, stress and mental health. Two thigh muscle biopsies and a subcutaneous adipose tissue fat sample from the abdominal region will be obtained, while maximal voluntary knee-extensor contraction torque and rate of force development will be measured. Lastly, cycling-based assessments of maximal fat oxidation rate, peak power and maximal oxygen uptake will be assessed using indirect calorimetry including capillary lactate samples.

The scan visit will consist of an MRI whole-body scan, soleus and gastrocnemius 1H-MRS and a pQCT bone scan of the lower limb at 4% and 66% of the total bone length.

The objective measurements of physical activity levels and glucose-handling capacity will be performed for 10 days in free-living conditions using feasibly worn sensors (continuous glucose monitor and thigh-worn accelerometer). During this time, a food dairy needs to be filled in during two week days and one weekend day to estimate the habitual food intake.

A standardized evening meal will be provided prior to the laboratory-based test day and a standardized lunch meal served during the testing day.

Тип исследования

Наблюдательный

Регистрация (Оцененный)

250

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Eline Lievens, Professor
  • Номер телефона: 00320478312585
  • Электронная почта: eline.lievens@ugent.be

Учебное резервное копирование контактов

Места учебы

  • Бельгия
    • East Flanders
      • Ghent, East Flanders, Бельгия, 9000
        • Рекрутинг
        • Ghent University
        • Контакт:
          • Eline Lievens, Professor
          • Номер телефона: 00320478312585
          • Электронная почта: eline.lievens@ugent.be
        • Контакт:

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

  • Взрослый

Принимает здоровых добровольцев

Н/Д

Метод выборки

Невероятностная выборка

Исследуемая популяция

Participants will be recruited from the greater Ghent area (Belgium) using recruitment materials including posters mounted on relevant locations (e.g. educational sites) and circulated on social media (e.g. Facebook, Linkedin, Twitter). The Gent University volunteer register of people who have expressed interest in participating in research studies will also be used.

Описание

Inclusion Criteria:

  • Sex: Males and females
  • Age: 20-30 years
  • BMI <35
  • Healthy (no diagnosed chronic disease)

Exclusion Criteria:

  • Chronic disease deemed to affect study outcomes
  • Disease that increase haemorrhage risk
  • Daily intake of medication that could confound study outcomes
  • Regular smokers
  • Active pregnancy
  • Immobilization (inactivity due to injury or illness, e.g. cast or brace) for more than a week in the month prior to the study or for more than 4 weeks in the past 6 months prior to the study
  • Very high structured physical exercise level (>10 h/week).
  • Participants not willing to adhere to standardized meal prescriptions included in the study protocols will also be excluded (due to e.g. allergies or specific dietary preferences)

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Whole-body insulin sensitivity
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
The Matsuda index derived from an oral glucose tolerance test
At baseline and at 5-year intervals for up to 20 years

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Skeletal muscle fiber type
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Skeletal muscle fiber type assessed using SDS page
At baseline and at 5-year intervals for up to 20 years
Molecular skeletal muscle profile
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Molecular profiling of skeletal muscle tissue, including proteomic and related pathway-level analyses relevant to metabolic function.
At baseline and at 5-year intervals for up to 20 years
MRI-derived muscle and fat volumes
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Whole-body MRI-derived muscle and fat volumes at the total and regional body level
At baseline and at 5-year intervals for up to 20 years
MRI derived tissue fat infiltration
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Whole-body MRI-derived tissue fat infiltration in the liver, intermuscular and intramuscular area
At baseline and at 5-year intervals for up to 20 years
Physical activity level
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Accelerometer-based physical activity levels
At baseline and at 5-year intervals for up to 20 years
HOMA-IR
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Homeostatic Model Assessment of Insulin Resistance based on fasted blood sampling
At baseline and at 5-year intervals for up to 20 years
Cardiorespiratory fitness
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Maximal oxygen uptake assessed using indirect calorimetry during incremental cycling
At baseline and at 5-year intervals for up to 20 years
Muscle strength
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Maximal voluntary isometric contraction torque assessed in a dynamometer
At baseline and at 5-year intervals for up to 20 years
Free-living glycaemic control
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Continuous glucose monitoring-derived glycaemic metrics during free-living conditions
At baseline and at 5-year intervals for up to 20 years
Dietary intake
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Dietary intake assessed using repeated 24-hour food diaries and food frequency questionnaires, including estimates of energy intake and macronutrient composition.
At baseline and at 5-year intervals for up to 20 years
Subcutaneous adipose tissue phenotyping
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Proteomics derived measures of adipose tissue phenotype
At baseline and at 5-year intervals for up to 20 years
Maximal fat oxidation rate
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Maximal fat oxidation rate obtained using indirect calorimetry during incremental cycling
At baseline and at 5-year intervals for up to 20 years
Pulsewave velocity
Временное ограничение: At baseline and at 5-years intervals for up to 20 years
Carotid-femoral pulsewave velocity measured using Doppler echocardiography with ECG gating
At baseline and at 5-years intervals for up to 20 years
Resting heart rate
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Resting heart rate assessed using a chest-worn heart rate monitor
At baseline and at 5-year intervals for up to 20 years
Heart rate variability
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Heart rate variability assessed using a chest-worn heart rate monitor
At baseline and at 5-year intervals for up to 20 years

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
Blood pressure
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Systolic and diastolic blood pressure obtained using a sphygmomanometer
At baseline and at 5-year intervals for up to 20 years
10 s sprint peak and average power
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Peak and average power output during a 10 s sprint test
At baseline and at 5-year intervals for up to 20 years
Lactate accumulation
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Lactate accumulation during a 10 s cycling sprint test
At baseline and at 5-year intervals for up to 20 years
Blood lipid profile
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Including measures of triglycerides, free fatty acids, lipoprotein (a), cholesterol, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol
At baseline and at 5-year intervals for up to 20 years
Bone measurements
Временное ограничение: At baseline and at 5-year intervals for up to 20 years
Bone density assessed using peripheral quantitative computed tomography (pQCT).
At baseline and at 5-year intervals for up to 20 years

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

University Ghent

Соавторы

University Hospital, Ghent

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

19 мая 2025 г.

Первичное завершение (Оцененный)

31 декабря 2046 г.

Завершение исследования (Оцененный)

31 декабря 2046 г.

Даты регистрации исследования

Первый отправленный

12 февраля 2026 г.

Впервые представлено, что соответствует критериям контроля качества

24 июня 2026 г.

Первый опубликованный (Действительный)

1 июля 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

1 июля 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

24 июня 2026 г.

Последняя проверка

1 июня 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • ONZ-2024-0588

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться